Terumo BCT and Marker Therapeutics received the first device FDA Emergency Use Authorization (EUA)

  • This topic is empty.
Viewing 1 post (of 1 total)
  • Author
    Posts
  • 04/10/2020 at 4:07 pm #4371
    Colorado BioScience AssocationColorado BioScience Association
    Keymaster

    Terumo BCT, Inc. and Marker Therapeutics AG announced today that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for the use of Terumo BCT’s Spectra Optia® Apheresis System combined with Marker Therapeutics’ D2000 Adsorption Cartridge to treat patients 18 years of age or older with confirmed Coronavirus Disease 2019 (COVID-19) admitted to the intensive care unit (ICU) with confirmed or imminent respiratory failure to reduce pro-inflammatory cytokine levels.

    Find out more in the press release. 

  • Author
    Posts
Viewing 1 post (of 1 total)
  • You must be logged in to reply to this topic.